



## 2020 challenge soft impact: slightly on revenues, operating profits and net income keep going as expected and production capacity doubling almost complete.

### NEUTRAL

Current Share Price (€): 0.281

Target Price (€): 0.323

#### Pierrel – Share Price Performance



Source: S&P Capital IQ - Note: 01/02/2020=100

#### Company data

ISIN number	IT0004007560
Bloomberg code	PRL IM
Reuters code	PRL.MI
Sector	Pharma & Healthcare
Stock market	MTA (Italy)
Share Price (€)	0.281
Date of Price	19/05/2021
Shares Outstanding (m)	228.9
Market Cap (€m)	64.3
Market Float (%)	28.6%
Daily Volume	615,525
Avg Daily Volume YTD	408,878
Target Price (€)	0.323
Upside (%)	15%
Recommendation	NEUTRAL

#### Share price performance

	1M	3M	1Y
Pierrel - Absolute (%)	1%	23%	64%
FTSE Italia Small Cap (%)	3%	14%	57%
1Y Range H/L (€)		0.190	0.115
YTD Change (€)/%		0.103	57%

Source: S&P Capital IQ

#### Analysts

Franco Gaudenti – Head of Research  
fgaudenti@enventcapitalmarkets.co.uk  
Luigi Tardella - Co-Head of Research  
ltardella@enventcapitalmarkets.co.uk

#### EnVent Capital Markets Limited

42, Berkeley Square - London W1J 5AW (UK)  
Phone +44 (0) 20 35198451

This document may not be distributed in the United States, Canada, Japan or Australia, or to U.S. persons.

#### Lockdowns affect revenues but not EBITDA; sound cash generation sustains capex

FY2020 revenues were €18.3m vs. €21.9m in 2019, -17% YoY, impacted by slowdowns in international orders and delivery delays. Partial recovery in Q4 especially in North America (+16% in sales of Orabloc® vs. Q4 2019). EBITDA was €3.2m, 17.5% margin only slightly below 2019 level of 20% thanks to cost management; net income of €1.9m did not suffer from 2020 uncertainty. Sound P/L cash flow generation sustained €4.2m capex for increase in production capacity.

On the balance sheet, net working capital was in line with 2019 at €0.2m, recording increases in receivables and inventory, typically linked to domestic and international lockdowns, offset by €2.3m of advances on year-end orders. Cash used for planned investments resulted in €7.8m net debt from €6.8m as of year-end 2019.

#### Industry outlook: distributors delay then recover orders, Pharma gains momentum

In 2020 Pierrel's industry experienced conflicting trends. While some healthcare distributors lost revenues due to delays of non-urgent dental care and only partially recovered in Q4, Pierrel's peers saw their revenues and margins unaffected by Covid-19 and were often rewarded by market in terms of higher multiples. Pierrel's performance lies between the two groups since it experienced revenue slowdown in 2020, while its share price outperformed, reducing its gap versus average industry multiples.

#### Doubling production capacity to catch coming opportunities

Pierrel, as aseptic injectable drugs specialist both authorized by EMA and FDA, is in the right position to cash in on the momentum gained from Pharma industry and on its marketing effort. In this regard, the investment plan undertaken in the last two years to double production capacity is enabling Pierrel to catch future market trends. For these reasons, we are assuming recovery from 2021 onwards.

#### Target Price €0.323 per share, from €0.246, NEUTRAL rating (from OUTPERFORM)

The DCF valuation, which reflects the revised short-term estimates, yields a Target Price of €0.323 per share (from €0.246), +15% potential upside on the current share price. We assign a NEUTRAL rating on the stock (from OUTPERFORM).

#### Key financials and estimates


€m	2017A	2018A	2019A	2020A	2021E	2022E	2023E
<b>Revenues</b>	<b>17.3</b>	<b>20.4</b>	<b>21.9</b>	<b>18.3</b>	<b>24.0</b>	<b>34.1</b>	<b>39.5</b>
YoY %	19.2%	17.7%	7.8%	-16.8%	31.4%	42.0%	15.9%
<b>EBITDA</b>	<b>2.1</b>	<b>3.4</b>	<b>4.4</b>	<b>3.2</b>	<b>5.0</b>	<b>7.9</b>	<b>9.9</b>
Margin	12.3%	16.5%	20.1%	17.5%	21.0%	23.1%	25.1%
<b>EBIT</b>	<b>1.0</b>	<b>2.3</b>	<b>3.3</b>	<b>2.0</b>	<b>3.4</b>	<b>6.1</b>	<b>8.1</b>
Margin	5.9%	11.3%	15.0%	10.9%	14.1%	18.0%	20.6%
<b>Net Income (Loss)</b>	<b>(2.5)</b>	<b>0.8</b>	<b>2.3</b>	<b>1.9</b>	<b>2.4</b>	<b>4.9</b>	<b>6.8</b>
<b>Net (Debt) Cash</b>	<b>(11.4)</b>	<b>(3.7)</b>	<b>(6.8)</b>	<b>(7.8)</b>	<b>(7.9)</b>	<b>(3.1)</b>	<b>4.3</b>
<b>Equity</b>	<b>2.3</b>	<b>11.3</b>	<b>13.5</b>	<b>15.4</b>	<b>17.8</b>	<b>22.7</b>	<b>29.5</b>

Source: Company data 2017-20A, EnVent Research 2021-22E

## Market update

Pierrel's share price gained 61% since February 2020, outperforming FTSE Italia Small Cap index, which in the same period increased by 20%. YTD at 55% vs. Small Cap index 23%.


### Pierrel - 1Y Share price performance and trading volumes



Source: EnVent Research on S&P Capital IQ - Note: 01/02/2020=100


Sharp increase in traded volumes in the first part of 2021

### Pierrel - Liquidity analysis and velocity turnover



Source: EnVent Research - Note: Velocity turnover on total shares: ratio of total traded shares to total ordinary shares in a given period


### Peer group - Regression analysis and Pierrel target positioning




Source: EnVent Research on S&P Capital IQ, May 2021

**FY20 impact: revenue -17% for orders slowdown; operating profit and net income just slightly below 2019 excellent performance.**

**Revenues by BU, 2020**



**Revenues by geography, 2020**



Source: Company data

In 2020, Pierrel consolidated revenues were €18.3m vs. €21.9m in 2019, -17% YoY, reflecting the impact of Covid-19 on international orders. BU Pharma, representing 74% of sales, experienced a minor decrease (-10% YoY), thanks to demand recovery in Q4 especially in the North American market (+16% in sales of Orabloc® vs. Q4 2019). EBITDA at €3.2m vs. €4.4m in FY19, despite lower sales nearly kept the same margin (17.5% vs. 20% in FY19), thanks to increasing share in higher gross margin revenues. EBIT was €2.0m (11% margin vs. 15% in 2019) and net income €1.9m (€2.3m in FY19). On the balance sheet, net working capital was in line with 2019 at €0.2m, recording increases in receivables and inventory, typically linked to domestic and international lockdowns, offset by €2.3m of advances on year-end orders.

Net financial debt increased to €7.8m, from €6.8m as of year-end 2019.

Breakdown:

- €3.9m cash from €5.5m in FY19; decrease related to planned investments.
- €0.5m bank debt
- €2.1m short-term financial debt
- €9.1m other financial debt

Operating cash flow, after working capital and capex of €6.4m, offset by €3.1m P/L cash generation and €2.3m of advances on year-end orders, resulted in a net financial debt increase of €1.0m.

**Business update**

**USA demand recovery in Q4**

**Orabloc® international expansion**

**Launch of GOCCLES®**

- Q4 2020 recorded a 16% growth in sales of the product Orabloc® in the USA vs Q4 2019; confirming a 23% market share.
- Pierrel added authorizations to market Orabloc®, its flagship dental anesthetic based on Articaine, in Bangladesh and Qatar.
- GOCCLES®, glasses for oral cancer light exposed early screening, awarded as preferred product 2021 by Dental Advisor (USA magazine).

**Outlook: marketing effort and new investments drive growth**

As expected, FY2020 results suffered from delayed non-urgent dental care in reference markets during Covid-19 lockdowns, as per revenue loss of distributors included in our industry performance and multiples analysis (See annex charts). We concur with management that the impact is expected to be temporary, as testified by orders increase in Q4. Anyway, a certain degree of uncertainty about backlashes in 2021 remains while there can be a recovery in the second part of the year.

We envisage further growth opportunities for Pierrel. The Pharma industry as a

**Industry update: not impacted by pandemic, and in some cases boosted. Distributors lose revenues for delay of non-urgent dental care**

whole has gained momentum because of the pandemic challenges and uncertainties. Pierrel, as injectables specialist which has just completed doubling its production capacity, has an increasing potential to cash in on marketing efforts. Moreover, by being authorized both by EMA and FDA for aseptic injectable drugs, Pierrel is expected to benefit from the growth in outsourcing market and by investments in new production lines and efficiency, to meet Orabloc®'s increase in orders.

Thus, we assume recovery in 2021 onwards, driven by constant marketing effort and PPE investments, together with positive cash flows.

#### Updated Management Guidance (April 2021)

€m	2019A	2020A	2021E
<b>Revenues</b>	21.9	18.3	24.0
<i>YoY%</i>	8%	-17%	31%
<b>EBITDA</b>	4.4	3.2	4.9
<i>Margin</i>	20%	17%	20%

#### Prior Management Guidance (September 2020)

€m	2019A	2020E	2021E
<b>Revenues</b>	21.9	19.1	28.4
<i>YoY%</i>	8%	-13%	49%
<b>EBITDA</b>	4.4	2.7	6.4
<i>Margin</i>	20%	14%	23%


Source: Company data

### Estimates revision

Since Covid-19 is expected to cause no harm to future growth opportunities, we are adjusting our estimates for 2021 to factor in 2020 actual figures and time required to recover pre-Covid sales levels. 2021 revenue and operating profit are in line with updated management guidelines, proven fairly reliable for prior periods. For the following years, we overall confirm our previous estimates in view of the progressive utilization of the additional production capacity coming from last two years' investments. We have also added 2023E to the forecasting period assuming consistent growth.

## Change in estimates

### Revenues and EBITDA (€m) - Previous vs. Revised estimates



€m	2020	Revised			Previous			Change %		
		2021E	2022E	2023E	2020E	2021E	2022E	2020	2021E	2022E
<b>Revenues</b>	18.3	24.0	34.1	39.5	19.4	27.2	34.3	-6%	-12%	-1%
<b>EBITDA</b>	3.2	5.0	7.9	9.9	3.0	5.3	7.3	6%	-5%	8%
<i>Margin</i>	17%	21%	23%	25%	15%	19%	21%			
<b>EBIT</b>	2.0	3.4	6.1	8.1	1.7	3.9	5.8	17%	-14%	6%
<i>Margin</i>	11%	14%	18%	21%	9%	14%	17%			
<b>Net Income</b>	1.9	2.4	4.9	6.8	0.9	2.9	4.6	113%	-17%	6%
<b>Net (Debt) Cash</b>	(7.8)	(7.9)	(3.1)	4.3	(5.7)	(3.5)	0.8			
<i>Net Debt / EBITDA</i>	2.5x	1.6x	0.4x	nm	1.9x	0.7x	nm			

Source: EnVent Research; Company data 2021

## Financial projections

### Consolidated Profit and Loss

€m	2017A	2018A	2019A	2020A	2021E	2022E	2023E
<b>Revenues</b>	17.3	20.4	21.9	18.3	24.0	34.1	39.5
<i>YoY %</i>	19%	18%	8%	-17%	31%	42%	16%
COGS	(6.0)	(7.4)	(7.6)	(5.9)	(8.2)	(11.6)	(13.4)
<b>Gross profit</b>	11.3	12.9	14.4	12.4	15.8	22.5	26.1
<i>Margin</i>	65.2%	63.5%	65.5%	67.8%	66.0%	66.0%	66.0%
Personnel	(5.0)	(5.8)	(6.1)	(5.5)	(6.3)	(8.2)	(9.1)
G&A	(3.2)	(2.6)	(2.5)	(2.5)	(2.8)	(3.2)	(3.6)
Marketing & Sales	(0.4)	(0.5)	(0.6)	(0.5)	(0.7)	(1.7)	(2.0)
Other operating costs	(0.6)	(0.7)	(0.8)	(0.7)	(1.0)	(1.5)	(1.5)
<b>EBITDA</b>	2.1	3.4	4.4	3.2	5.0	7.9	9.9
<i>Margin</i>	12.3%	16.5%	20.1%	17.5%	21.0%	23.1%	25.1%
D&A	(1.1)	(1.0)	(1.1)	(1.2)	(1.6)	(1.8)	(1.8)
<b>EBIT</b>	1.0	2.3	3.3	2.0	3.4	6.1	8.1
<i>Margin</i>	5.9%	11.3%	15.0%	10.9%	14.1%	18.0%	20.6%
Interest	(1.2)	(0.9)	(0.8)	(0.0)	(0.7)	(0.7)	(0.7)
Exchange gain (loss)	1.0	0.0	0.0	0.0	0.0	0.0	0.0
Non-recurring items	(3.1)	(0.3)	0.0	0.0	0.0	0.0	0.0
<b>EBT</b>	(2.3)	1.1	2.5	2.0	2.6	5.4	7.4
<i>Margin</i>	-13.1%	5.5%	11.3%	10.7%	11.0%	15.8%	18.8%
Income taxes	(0.2)	(0.3)	(0.2)	(0.0)	(0.2)	(0.5)	(0.7)
<b>Net Income (Loss)</b>	(2.5)	0.8	2.3	1.9	2.4	4.9	6.8
<i>Margin</i>	-14.5%	4.2%	10.3%	10.5%	10.0%	14.4%	17.1%

Source: Company data 2017-20A; EnVent Research 2021-23E

### Consolidated Balance Sheet

€m	2017A	2018A	2019A	2020A	2021E	2022E	2023E
Inventory	2.8	3.8	3.3	4.1	4.6	5.6	6.0
Trade receivables	3.3	3.3	2.4	3.7	4.4	5.7	5.9
Trade payables	(4.9)	(4.5)	(3.0)	(2.8)	(3.4)	(4.8)	(5.5)
Trade Working Capital	1.2	2.6	2.8	4.9	5.6	6.5	6.4
Other assets (liabilities)	(4.0)	(4.0)	(2.4)	(4.7)	(2.5)	(2.5)	(2.5)
<b>Net Working Capital</b>	<b>(2.8)</b>	<b>(1.4)</b>	<b>0.3</b>	<b>0.2</b>	<b>3.1</b>	<b>4.0</b>	<b>3.9</b>
Intangible assets	1.4	2.0	2.3	3.2	3.3	3.3	3.3
Property, plant and equipment	10.2	9.5	12.7	14.9	14.3	13.7	13.2
Deferred tax assets	5.3	5.3	5.3	5.3	5.3	5.3	5.3
Financial assets	0.1	0.0	0.0	0.0	0.0	0.0	0.0
<b>Non-current assets</b>	<b>17.0</b>	<b>16.8</b>	<b>20.3</b>	<b>23.3</b>	<b>22.9</b>	<b>22.3</b>	<b>21.8</b>
<b>Provisions</b>	<b>(0.5)</b>	<b>(0.4)</b>	<b>(0.3)</b>	<b>(0.3)</b>	<b>(0.4)</b>	<b>(0.5)</b>	<b>(0.5)</b>
<b>Net Invested Capital</b>	<b>13.7</b>	<b>15.0</b>	<b>20.3</b>	<b>23.2</b>	<b>25.7</b>	<b>25.8</b>	<b>25.1</b>
<b>Net Debt (Cash)</b>	<b>11.4</b>	<b>3.7</b>	<b>6.8</b>	<b>7.8</b>	<b>7.9</b>	<b>3.1</b>	<b>(4.3)</b>
<b>Equity</b>	<b>2.3</b>	<b>11.3</b>	<b>13.5</b>	<b>15.4</b>	<b>17.8</b>	<b>22.7</b>	<b>29.5</b>
<b>Sources</b>	<b>13.7</b>	<b>15.0</b>	<b>20.3</b>	<b>23.2</b>	<b>25.7</b>	<b>25.8</b>	<b>25.1</b>

Source: Company data 2017-20A; EnVent Research 2021-23E

### Consolidated Cash Flow

€m	2017A	2018A	2019A	2020A	2021E	2022E	2023E
<b>EBIT</b>	<b>1.0</b>	<b>2.3</b>	<b>3.3</b>	<b>2.0</b>	<b>3.4</b>	<b>6.1</b>	<b>8.1</b>
Current taxes	(0.2)	(0.3)	(0.2)	(0.0)	(0.2)	(0.5)	(0.7)
D&A	1.1	1.0	1.1	1.2	1.6	1.8	1.8
Provisions	(0.0)	(0.2)	(0.0)	(0.0)	0.0	0.1	0.0
<b>Cash flow from P&amp;L operations</b>	<b>1.8</b>	<b>2.9</b>	<b>4.2</b>	<b>3.1</b>	<b>4.8</b>	<b>7.5</b>	<b>9.3</b>
Trade Working Capital	(1.8)	(1.4)	(0.2)	(2.2)	(0.7)	(0.9)	0.1
Other assets and liabilities	3.2	(0.0)	(1.6)	2.3	(2.2)	0.0	0.0
Capex	(0.9)	(0.8)	(4.6)	(4.2)	(1.2)	(1.2)	(1.2)
Deferred tax assets	0.1	0.0	0.0	0.0	0.0	0.0	0.0
<b>Operating cash flow after workin</b>	<b>2.4</b>	<b>0.7</b>	<b>(2.2)</b>	<b>(1.0)</b>	<b>0.7</b>	<b>5.5</b>	<b>8.2</b>
Interest	(1.2)	(0.9)	(0.8)	(0.0)	(0.7)	(0.7)	(0.7)
Exchange gain (loss)	1.0	0.0	0.0	0.0	0.0	0.0	0.0
Non-recurring items	(3.1)	(0.3)	0.0	0.0	0.0	0.0	0.0
Capital increase (decrease)	12.3	8.2	(0.1)	(0.0)	0.0	0.0	0.0
<b>Net cash flow</b>	<b>11.4</b>	<b>7.8</b>	<b>(3.1)</b>	<b>(1.0)</b>	<b>(0.1)</b>	<b>4.7</b>	<b>7.5</b>
Net (Debt) Cash - Beginning	(22.9)	(11.4)	(3.7)	(6.8)	(7.8)	(7.9)	(3.1)
Net (Debt) Cash - End	(11.4)	(3.7)	(6.8)	(7.8)	(7.9)	(3.1)	4.3
<b>Change in Net (Debt) Cash</b>	<b>11.4</b>	<b>7.8</b>	<b>(3.1)</b>	<b>(1.0)</b>	<b>(0.1)</b>	<b>4.7</b>	<b>7.5</b>

Source: Company data 2017-20A; EnVent Research 2021-22E

**Ratio analysis**

KPIs	2017A	2018A	2019A	2020A	2021E	2022E	2023E
ROE	-112%	7%	17%	12%	14%	22%	23%
ROS (EBIT/Revenues)	6%	11%	15%	11%	14%	18%	21%
ROIC (NOPAT/Invested Capital)	6%	11%	12%	6%	9%	17%	23%
DSO	58	49	33	60	55	50	45
DPO	144	121	78	89	80	80	80
DOI	59	68	56	81	60	60	55
TWC/Revenues	7%	13%	13%	27%	23%	19%	16%
NWC/Revenues	-16%	-7%	1%	1%	13%	12%	10%
Net Debt / EBITDA	5.4x	1.1x	1.5x	2.5x	1.6x	cash	cash
Cash flow from P&L operations /	86%	87%	94%	99%	96%	95%	94%
FCF / EBITDA	115%	22%	neg.	neg.	14%	69%	83%
EPS	neg.	0.00	0.01	0.01	0.01	0.02	0.03

Source: Company data 2017-20A; EnVent Research 2021-22E

## Valuation: industry peers keep their performance, 2020 slowdowns among distributors.

We have carried on and updated our DCF valuation model. We have also updated market multiples and the regression analysis and noticed limited fluctuations in multiples of the industry as a whole. Pierrel operating profit performance sustains implied multiples consistent with industry range resulting from our analysis.

### Discounted Cash Flows

Updated assumptions:

- Risk free rate: 1.5% (Italian 10-year government bonds interest rate - 3Y average. Source: Bloomberg, April 2021)
- Market return: 12.6% (3Y average. Source: Bloomberg, April 2021)
- Market risk premium: 11.1%
- Beta: 1 (Median of core business peers. Source: Bloomberg)
- Cost of equity: 12.9%
- Cost of debt: 3.5%
- Tax rate: 24% IRES
- 50% debt/(debt + equity) as target capital structure
- WACC calculated at 7.8%, according to above data
- Perpetual growth rate after explicit projections 2.5%
- Terminal Value assumes EBITDA margin at 20% and EBIT margin at 17%

DCF Valuation								
€m	2017A	2018A	2019A	2020A	2021E	2022E	2023E	Perpetuity
<b>Revenues</b>	<b>17.3</b>	<b>20.4</b>	<b>21.9</b>	<b>18.3</b>	<b>24.0</b>	<b>34.1</b>	<b>39.5</b>	<b>40.4</b>
<b>EBITDA</b>	<b>2.1</b>	<b>3.4</b>	<b>4.4</b>	<b>3.2</b>	<b>5.0</b>	<b>7.9</b>	<b>9.9</b>	<b>8.1</b>
<i>Margin</i>	12.3%	16.5%	20.1%	17.5%	21.0%	23.1%	25.1%	20.0%
<b>EBIT</b>	<b>1.0</b>	<b>2.3</b>	<b>3.3</b>	<b>2.0</b>	<b>3.4</b>	<b>6.1</b>	<b>8.1</b>	<b>6.9</b>
<i>Margin</i>	5.9%	11.3%	15.0%	10.9%	14.1%	18.0%	20.6%	17.0%
Taxes	(0.2)	(0.7)	(1.0)	(0.6)	(1.0)	(1.8)	(2.4)	(2.0)
<b>NOPAT</b>	<b>0.8</b>	<b>1.6</b>	<b>2.3</b>	<b>1.4</b>	<b>2.4</b>	<b>4.3</b>	<b>5.8</b>	<b>4.9</b>
D&A	1.1	1.0	1.1	1.2	1.6	1.8	1.8	1.2
Provisions	(0.0)	(0.2)	(0.0)	(0.0)	0.0	0.1	0.0	0.1
<b>Cash flow from P&amp;L operations</b>	<b>1.8</b>	<b>2.5</b>	<b>3.4</b>	<b>2.6</b>	<b>4.1</b>	<b>6.2</b>	<b>7.6</b>	<b>6.2</b>
Trade Working Capital	(1.8)	(1.4)	(0.2)	(2.2)	(0.7)	(0.9)	0.1	(0.2)
Other assets and liabilities	3.2	(0.0)	(1.6)	2.3	(2.2)	0.0	0.0	0.0
Capex	(0.9)	(0.8)	(4.6)	(4.2)	(1.2)	(1.2)	(1.2)	(1.2)
<b>Unlevered free cash flow</b>	<b>2.3</b>	<b>0.3</b>	<b>(2.9)</b>	<b>(1.5)</b>	<b>(0.1)</b>	<b>4.2</b>	<b>6.5</b>	<b>4.8</b>
WACC	7.8%							
Long-term growth (G)	2.5%							
<b>Discounted Cash Flows</b>					<b>(0.1)</b>	<b>3.6</b>	<b>5.2</b>	
Sum of Discounted Cash	8.7							
<b>Terminal Value</b>								<b>90.3</b>
Discounted TV	72.1							
<b>Enterprise Value</b>	<b>80.8</b>							
Net Debt as of 31/12/20	(7.8)							
Short-term tax relief	0.9							
<b>Equity Value</b>	<b>73.9</b>							
<b>DCF - Implied multiples</b>	<b>2018A</b>	<b>2019A</b>	<b>2020A</b>	<b>2021E</b>	<b>2022E</b>			
EV/Revenues	4.0x	3.7x	4.4x	3.4x	2.4x			
EV/EBITDA	24.1x	18.3x	25.3x	16.1x	10.2x			
EV/EBIT	35.0x	24.5x	40.6x	23.9x	13.2x			
P/E	87.3x	32.8x	38.5x	30.7x	15.0x			

Source: EnVent Research

## Target Price

Our valuation of Pierrel on updated estimates is at €0.323 per share, compared to our prior target price of €0.246, with a potential upside of 15% on the current share price. Thus, we assign a NEUTRAL recommendation on the stock (from OUTPERFORM).

### Pierrel Price per Share

<b>Target Price</b>	<b>0.323</b>
Current Share Price (19/05/2021)	0.281
<b>Premium (Discount)</b>	<b>15%</b>

Source: EnVent Research

Please refer to important disclosures at the end of this report.



## Annex

### Peer Group - Market Multiples

Company	EV/REVENUES				EV/EBITDA				EV/EBIT				P/E			
	2019	2020	2021E	2022E	2019	2020	2021E	2022E	2019	2020	2021E	2022E	2019	2020	2021E	2022E
Pierrel	2.1x	3.6x	2.6x	2.1x	10.5x	23.6x	13.3x	9.7x	14.1x	40.7x	18.0x	12.2x	17.6x	70.8x	21.6x	13.6x
<b>Core business peers</b>																
Lonza	7.1x	9.8x	9.0x	8.2x	21.0x	30.7x	28.2x	24.7x	32.3x	45.7x	35.8x	31.1x	40.7x	47.1x	41.9x	36.5x
Catalent	4.4x	5.9x	5.0x	4.5x	21.0x	27.4x	19.5x	16.7x	37.2x	44.4x	25.4x	21.7x	60.8x	73.0x	33.7x	27.7x
West Pharmaceutical Services	6.0x	11.2x	8.9x	8.2x	27.6x	45.6x	30.4x	27.7x	37.2x	57.4x	36.0x	32.6x	46.0x	70.1x	44.4x	41.2x
Laboratorios Farmaceuticos ROVI	3.6x	6.4x	5.2x	4.5x	24.7x	29.0x	22.3x	19.4x	32.6x	34.5x	27.3x	22.9x	34.4x	43.5x	29.1x	26.9x
Baxter International	4.0x	3.9x	3.6x	3.4x	16.4x	17.0x	14.9x	14.3x	22.8x	24.4x	19.3x	17.2x	42.7x	38.4x	23.3x	20.6x
Thermo Fisher Scientific	5.7x	6.0x	5.4x	5.4x	22.4x	19.1x	16.7x	18.6x	34.3x	24.7x	17.9x	20.4x	35.2x	28.4x	20.3x	23.2x
Mean	5.1x	7.2x	6.2x	5.7x	22.2x	28.1x	22.0x	20.2x	32.7x	38.5x	26.9x	24.3x	43.3x	50.1x	32.1x	29.3x
Median	5.0x	6.2x	5.3x	5.0x	21.7x	28.2x	20.9x	19.0x	33.5x	39.4x	26.3x	22.3x	41.7x	45.3x	31.4x	27.3x
<b>Customers/Distributors</b>																
Patterson	0.5x	0.6x	0.7x	0.7x	10.1x	13.2x	12.7x	12.0x	14.9x	19.1x	14.6x	13.8x	23.0x	neg	16.8x	16.3x
Henry Schein	1.2x	1.3x	1.1x	1.1x	12.6x	18.0x	13.1x	12.6x	15.8x	24.1x	16.1x	15.7x	14.0x	27.6x	19.1x	18.3x
Dentsply	3.4x	5.0x	3.9x	3.7x	17.3x	27.6x	16.2x	14.8x	29.2x	61.5x	18.6x	17.0x	47.9x	neg	22.6x	20.4x
Mean	1.7x	2.3x	1.9x	1.8x	13.3x	19.6x	14.0x	13.1x	20.0x	34.9x	16.4x	15.5x	28.3x	27.6x	19.5x	18.3x
Median	1.2x	1.3x	1.1x	1.1x	12.6x	18.0x	13.1x	12.6x	15.8x	24.1x	16.1x	15.7x	23.0x	27.6x	19.1x	18.3x

Source: S&P Capital IQ, May 2021

### Peer Group – Key Data

Company	Revenues 2019 (€m)	Revenues 2020 (€m)	Rev. YoY 20-19 %	Rev. CAGR '20-22E	EBITDA % 2020	EBITDA % Avg. 5Y	EBITDA % Min 5Y	EBITDA % Max 5Y
<b>Core business peers</b>								
Lonza	3,871	4,165	8%	10%	32%	28%	22%	34%
Catalent	2,213	2,750	24%	14%	21%	20%	19%	21%
West Pharmaceutical Services	1,640	1,755	7%	17%	25%	22%	21%	25%
Laboratorios Farmaceuticos ROVI	381	420	10%	22%	22%	13%	9%	22%
Baxter International	10,125	9,543	-6%	7%	23%	22%	19%	24%
Thermo Fisher Scientific	22,760	26,338	16%	5%	32%	27%	25%	32%
Mean			10%	13%	26%	22%	19%	26%
Median			9%	12%	24%	22%	20%	25%
<b>Customers/Distributors</b>								
Patterson	4,994	5,085	2%	0%	5%	6%	5%	8%
Henry Schein	8,936	8,304	-7%	9%	7%	9%	7%	9%
Dentsply	3,590	2,732	-24%	16%	18%	19%	17%	21%
Mean			-10%	8%	10%	11%	10%	13%
Median			-7%	9%	7%	9%	7%	9%

Source: S&P Capital IQ, May 2021

## Investment case

### Company

Pierrel SpA (PRL) is a global supplier of dental anesthetics and other products, specializing in CMO (Contract Manufacturing Organization) of injectable products under their proprietary brands or distributor-branded products. The CMO Business Unit provides a range of manufacturing services for injectable formulations for pharmaceutical companies that have chosen to outsource their production processes. The Pharma BU manages the registration and marketing of proprietary dental anesthetics branded Pierrel, entirely manufactured in-house, as well as the development and marketing of innovative medical devices and new drugs. Pierrel recently completed its operational and financial turnaround after the divestment of a loss-making non-core business.

- Sales (2020): €18.3, 15% CAGR 2016-2019
- Geographical breakdown (2020): North America 57%, Europe 37%, RoW 6%
- Market share of the flagship product Orabloc® in the dental anesthetics market based on Articaine in the USA (2020): 23%
- Employees (2019): 96

### Revenue drivers

Pierrel, as one of the largest global producers of Articaine and Lidocaine and the only FDA authorized outside the USA, is a first choice supplier for North American and international dental products distributors which see room to rebalance market shares in a segment where the market leader has its own distribution and a market share higher than 50% in the US and even more internationally.

Pierrel's business model implies high visibility on the top line, which is driven by sales of large and well-established distributors to end customers. Major distribution contracts in this industry last several years, with an history of recurring and growing orders. Additional agreements with distributors are mid/long-term too. As such, a substantial portion of Pierrel's revenues over the years comes consistently from recurring major customers.

## Drivers

### Industry drivers

**Dental anesthesia market steadily growing.** The increasing dental health checkups, introduction of new products, new investments in dental research and increasing geriatric population are the key factors driving growth of the dental anesthesia market, expected to grow steadily at a moderate pace globally.

**Dental anesthetics coverage shows room for growth.** The dental anesthesia market is segmented mainly into Articaine, Lidocaine, Mepivacaine, Prilocaine, Bupivacaine. In the USA the use of Lidocaine exceeds that of Articaine, because Lidocaine was introduced in 70s, while

Articaine in 2000s; in addition, Articaine is more expensive than Lidocaine. Articaine is the market leader in Europe, Russia, CIS countries. Articaine and Lidocaine share the market equally in the USA. Lidocaine is the market leader in emerging markets. Pierrel, as one of the largest global producers of Articaine and Lidocaine, is in the best position to enter new markets and benefit of the growing demand.

**On the tail of pharma trend, CMO on the rise.** As incomes rise and populations age, drugs costs continue to rise and the growing demand for lower cost alternatives to novel therapies surges, due to time and investment necessary to bring complex drugs to market. Since many traditional pharma companies lack such expertise, they often turn to CMOs who have the expertise in developing and manufacturing generics and biologic drugs.

**Product and service quality driving demand for CMO.** CMO accelerates product development timeframes and go-to-market, reduces costs in order to better compete internationally and efficiently addresses regulatory and compliance issues. Key factors are product and service quality, while price is a second-tier selection criteria.

**Patent expiry.** The expirations of patents in the mid-term will affect several products made by originators, representing new growth opportunities for CMO players. As aging patents begin to expire and competition heats up, pharma firms are recognizing the urgency in leveraging novel, proprietary technologies to achieve product differentiation - expertise and resources provided by CMOs.

**Dental equipment market growing rapidly.** The global dental equipment market is expected to grow steadily in the upcoming years, driven by the growing ageing population, increasing demand for cosmetic dentistry, increasing dental diseases, innovation in dental products, diagnostics and treatment-related technologies. North America is leading the global dental equipment market, Europe following closely. Asian countries, such as India, China, South Korea, Malaysia, Thailand, and Singapore are likely to provide a growing market due to their increasing per capita income and investments in healthcare.

**Management of hedge risk and “gap capacity”.** Pharmaceutical companies often outsource to balance their risk and buy time until key milestones in clinical trials or market uptake are met and they can justify investing in-house. Also, outsourcing is a strategic option for large pharma companies switching over parts of their pipeline to biopharma and new market entrants and start-ups developing pharmaceuticals lacking existing manufacturing capabilities.

### **Company drivers**

**Reliable manufacturing capabilities and high product quality combined with strong FDA and EMA record.** In the CMO business, state-of-the-art production plants and manufacturing of effective and quality products are key to obtain approvals from drugs associations. PRL leverages on this key competitive advantage as a fundamental requirement to enlarge customers portfolio and compete with the CMO leaders. Pierrel’s production plant is authorized by AIFA (Italian Medicines Agency), EMA (European Medicines Agency) and FDA (US Food and Drug Administration) for the production of aseptic injectable drugs.

**One-stop full service provider.** Pierrel combines the development, registration and licensing of new drugs and medical devices with drug manufacturing in the dental anesthesia market, fully serving its customers. Offering a multitude of services creates the opportunity for Pierrel to sell more products to the same customer, as well as develop lock-in models through increased switching costs. In doing so, large and small customers are fully serviced improving time and costs efficiency.

**Long-term relationships with main industry distributors, leading to high revenue visibility.** Thanks to over 60 years of history, Pierrel relies on its well-established presence in Europe and North America. The nature of the business and Pierrel's track record give high visibility on the top-line, given that CMO contracts generally last a minimum of two years and Pharma contracts usually start from five years. In addition, both are often automatically renewed.

**Established presence in Europe and USA and potential expansion into countries with rapid growth.** Pierrel's flagship product, Orabloc®, dental anesthetic based on Articaine, has a market share of 23% in the USA. Exports to North America account for 50% of 2019 revenues.

**Technical know-how.** Pierrel has technical capabilities in drug development, process development and scale-up, and is well-suited to production process development, able to increase yields while reducing COGS. In fact, a CMO's technical know-how is one of the most important factors to consider when selecting an outsourcer, along with its track record of quality, compliance inspection and supply flexibility.

**Highly skilled and committed management team with a long track record in the pharmaceutical sector.** Pierrel management team has post-graduate degrees in pharmaceutical and chemical majors. Around 35% of employees have specializations or proven pharmaceutical, chemical and quality control technical know-how.

**Production capacity to double by 2020.** In order to sustain the future demand and its marketing program in the USA and other selected countries, Pierrel has planned to increase its production capacity up to doubling, adding a new production line for cartridges. The start-up of the new production line is currently scheduled for 2020. The investment, estimated in €9m, includes around €2m development and registration costs for the marketing authorization of a new molecule to be marketed in North America.

**Rationale of marketing strategy.** In the CMO BU growth in the volume of cartridges and new pharmaceutical specialties on the North American market. In the Pharma BU, growth in sales of Orabloc® through agreements with the largest global US and European dental care distributors; launch of products in new markets (Far East, Middle East, CIS regions, Africa) where marketing authorizations have been already obtained.

**Operational leverage.** Overheads reduction in 2017-2018, together with the planned investment to double production capacity, should generate significant cost efficiencies, leading to an improved operational leverage and increasing operating margins.

## Challenges

**Revenue concentration.** Europe and North America account for ca. 90% of consolidated revenues. The additional registrations and distributors in new geographies are going to decrease progressively customer concentration.

**Contract duration.** CMO and Pharma contracts, despite being long-term contracts generally lasting at least 2-5 years, are subject to renewal and in most cases do not require a minimum supply.

**Execution delivery risk.** Delivering products and services not in line with regulation and customer expectations due to cost/time overruns, and quality issues, may impact margins and reputation. Any unplanned interruption or limitation of the production capacity of the Capua plant could lead to delays or interruptions in the delivery of products.

**Reliance on key suppliers.** The choice of suppliers follows strict selection criteria that ensure adequate levels of service or that have particular skills or qualifications according to the GMP standards, as well as the necessary authorizations issued by AIFA and the Italian Ministry of Health. The authorization process for the selection of a qualified supplier or for its replacement can represent an issue as to time and charges and is subject to several authorizations.

**DISCLAIMER** (for more details go to [www.enventcapitalmarkets.co.uk](http://www.enventcapitalmarkets.co.uk) under “Disclaimer”)

This publication has been prepared by Franco Gaudenti, Head of Research Division, and Luigi Tardella, Co-Head of Research Division, on behalf of the Research & Analysis Division of EnVent Capital Markets Limited (“EnVentCM”). EnVent Capital Markets Limited is authorised and regulated by the Financial Conduct Authority (Reference no. 651385).

This publication does not represent to be, nor can it be construed as being, an offer or solicitation to buy, subscribe or sell financial products or instruments, or to execute any operation whatsoever concerning such products or instruments. This publication is not, under any circumstances, intended for distribution to the general public. Accordingly, this document is only for persons who are Eligible Counterparties or Professional Clients only, i.e. persons having professional experience in investments who are authorized persons or exempted persons within the meaning of the Financial Services and Markets Act 2000 and COBS 4.12 of the FCA’s New Conduct of Business Sourcebook. For residents in Italy, this document is intended for distribution only to professional clients and qualified counterparties as defined in Consob Regulation n. 16190 of the 29th October 2007, as subsequently amended and supplemented.

EnVentCM does not guarantee any specific result as regards the information contained in the present publication, and accepts no responsibility or liability for the outcome of the transactions recommended therein or for the results produced by such transactions. Each and every investment/divestiture decision is the sole responsibility of the party receiving the advice and recommendations, who is free to decide whether or not to implement them. The price of the investments and the income derived from them can go down as well as up, and investors may not get back the amount originally invested. Therefore, EnVentCM and/or the author(s) of the present publication cannot in any way be held liable for any losses, damage or lower earnings that the party using the publication might suffer following execution of transactions on the basis of the information and/or recommendations contained therein.

The purpose of this publication is merely to provide information that is up to date and as accurate as possible. The information and each possible estimate and/or opinion and/or recommendation contained in this publication is based on sources believed to be reliable. Although EnVentCM makes every reasonable endeavour to obtain information from sources that it deems to be reliable, it accepts no responsibility or liability as to the completeness, accuracy or exactitude of such information and sources. Past performance is not a guarantee of future results.

Most important sources of information used for the preparation of this publication are the documentation published by the Company (annual and interim financial statements, press releases, company presentations, IPO prospectus), the information provided by business and credit information providers (as Bloomberg, S&P Capital IQ, AIDA) and industry reports.

EnVentCM has no obligation to update, modify or amend this publication or to otherwise notify a reader or recipient of this publication in the case that any matter, opinion, forecast or estimate contained herein, changes or subsequently becomes inaccurate, or if the research on the subject company is withdrawn. The estimates, opinions, and recommendations expressed in this publication may be subject to change without notice, on the basis of new and/or further available information.

EnVentCM intends to provide continuous coverage of the Company and the financial instrument forming the subject of the present publication, with a semi-annual frequency and, in any case, with a frequency consistent with the timing of the Company’s periodical financial reporting and of any exceptional event occurring in its sphere of activity.

A draft copy of this publication may be sent to the subject Company for its information and review (without target price and/or recommendation), for the purpose of correcting any inadvertent material inaccuracies. EnVentCM did not disclose the rating to the issuer before publication and dissemination of this document.

This publication, nor any copy of it, can not be brought, transmitted or distributed in the United States of America, Canada, Japan or Australia. Any failure to comply with these restrictions may constitute a violation of the securities laws provided by the United States of America, Canada, Japan or Australia.

EnVentCM is distributing this publication as from the date indicated on the front page of this publication.

#### **ANALYST DISCLOSURES**

For each company mentioned in this publication, all of the views expressed in this publication accurately reflect the financial analysts’ personal views about any or all of the subject company (companies) or securities.

Neither the analysts nor any member of the analysts’ households have a financial interest in the securities of the subject company. Neither the analysts nor any member of the analysts’ households serve as an officer, director or advisory board member of the subject company. Analysts’ remuneration was not, is not or will be not related, either directly or indirectly, to specific proprietary investment transactions or to market operations in which EnVentCM has played a role (as Nomad, for example) or to the specific recommendation or view in this publication. EnVentCM has adopted internal procedures and an internal code of conduct aimed to ensure the independence of its financial analysts. EnVentCM research analysts and other staff involved in issuing and disseminating research reports operate independently of EnVentCM Capital Market business. EnVentCM, within the Research & Analysis Division, may collaborate with external professionals. It may, directly or indirectly, have a potential conflict of interest with the Company and, for that reason, EnVentCM adopts organizational and procedural measures for the prevention and management of conflicts of interest (for details [www.enventcapitalmarkets.co.uk](http://www.enventcapitalmarkets.co.uk) under “Disclaimer”, “Procedures for prevention of conflicts of interest”).

## MIFID II DISCLOSURES

**Pierrel S.p.A.** (the “Issuer or the “Company”) is a corporate client of EnVentCM. This document, being paid for by a corporate Issuer, is a Minor Non-monetary Benefit as set out in Article 12 (3) of the Commission Delegated Act (C2016) 2031.

This note is a marketing communication and not independent research. As such, it has not been prepared in accordance with legal requirements designed to promote the independence of investment research and this note is not subject to the prohibition on dealing ahead of the dissemination of investment research.

## CONFLICTS OF INTEREST

In order to disclose its possible conflicts of interest, EnVentCM states that it acts or has acted in the past 12 months as Nominated Adviser (“Nomad”) to the subject Company on the AIM Italia market, a Multilateral Trading Facility regulated by Borsa Italiana (for details [www.enventcapitalmarkets.co.uk](http://www.enventcapitalmarkets.co.uk) under “Disclaimer”, “Potential conflicts of interest”).

## CONFIDENTIALITY

Neither this publication nor any portions thereof (including, without limitation, any conclusion as to values or any individual associated with this publication or the professional associations or organizations with which they are affiliated) shall be reproduced to third parties by any means without the prior written consent and approval from EnVentCM.

## VALUATION METHODOLOGIES

EnVentCM Research & Analysis Division calculates range of values and fair values for the companies under coverage using professional valuation methodologies, such as the discounted cash flows method (DCF), dividend discount model (DDM) and multiple-based models (e.g. EV/Revenues, EV/EBITDA, EV/EBIT, P/E, P/BV). Alternative valuation methodologies may be used, according to circumstances or judgement of non-adequacy of most used methods. The target price could be also influenced by market conditions or events and corporate or share peculiarities.

## STOCK RATINGS

The “OUTPERFORM”, “NEUTRAL”, AND “UNDERPERFORM” recommendations are based on the expectations within 12-month period of date of initial rating (shown in the chart on the front page of this publication). Equity ratings and valuations are issued in absolute terms, not relative to market performance.

Rating rationale:

OUTPERFORM: stocks are expected to have a total return of at least 20% in the mid-term;

NEUTRAL: stocks are expected to have a performance consistent with market or industry trend and appear less attractive than Outperform rated stocks;

UNDERPERFORM: stocks are among the least attractive in a peer group;

UNDER REVIEW: target price under review, waiting for updated financial data, or other key information such as material transactions involving share capital or financing;

SUSPENDED: no rating/target price assigned, due to material uncertainties or other issues that seriously impair our previous investment ratings, price targets and earnings estimates;

NOT RATED: no rating or target price assigned.

The stock price indicated is the reference price on the day indicated as “Date of Price” in the table on the front page of this publication.

## DETAILS ON STOCK RECOMMENDATION AND TARGET PRICE

Pierrel

Date	Recommendation	Target Price (€)	Share Price (€)
13/09/2018	NOT RATED	n.a.	0.154
11/06/2019	NEUTRAL	0.267	0.175
18/09/2019	OUTPERFORM	0.271	0.164
08/05/2020	OUTPERFORM	0.247	0.170
13/10/2020	OUTPERFORM	0.246	0.286
19/05/2021	NEUTRAL	0.323	0.281

## ENVENTCM RECOMMENDATION DISTRIBUTION (May 19<sup>th</sup>, 2021)

Number of companies covered:	19	OUTPERFORM	NEUTRAL	UNDERPERFORM	SUSPENDED	UNDER REVIEW	NOT RATED
Total Equity Research Coverage %		74%	21%	0%	0%	5%	0%
of which EnVentCM clients % *		100%	100%	0%	0%	100%	0%

\* Note: Companies to which corporate and capital markets services were supplied in the last 12 months.

This disclaimer is constantly updated on the website at [www.enventcapitalmarkets.co.uk](http://www.enventcapitalmarkets.co.uk) under “Disclaimer”.

Additional information available upon request.

© Copyright 2021 by EnVent Capital Markets Limited - All rights reserved.